P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)

Detalles Bibliográficos
Autores principales: Nastoupil, L. J., O’Brien, S., Holmes, H. E., Dsouza, L., Hart, D., Matsuda, E., Satterfield-Ledbetter, T., Skoble, J., Garner, E., Bryan, M., Kanner, S., Li, E., Thomas, C. T., Essell, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431188/
http://dx.doi.org/10.1097/01.HS9.0000848676.15840.df

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431188/
http://dx.doi.org/10.1097/01.HS9.0000848676.15840.df

Ejemplares similares